Waters Completes $10.8B Merger with BD's Biosciences Unit, Issues 38.5M Shares
Waters Corporation (NYSE: WAT) completed its $10.8 billion combination with Becton, Dickinson and Company's (BD) Biosciences and Diagnostic Solutions business on February 9, 2026, issuing 38.5 million shares to BD shareholders and assuming $4 billion in new term debt to finance the transaction.
The Deal
The transaction, first announced in July 2025, was structured as a Reverse Morris Trust that allowed BD to spin off its Biosciences division tax-free. BD shareholders received one share of the spun-off entity (SpinCo) for each BD share held as of February 5, 2026, which then converted to 0.135 shares of Waters stock per SpinCo share.
Following the merger, BD shareholders own approximately 39.2% of Waters' outstanding shares, while legacy Waters shareholders retain 60.8% ownership on a fully diluted basis. The SpinCo business also made a $4 billion cash payment to BD prior to the distribution, funded through new term loans.
Waters financed the cash portion through a $4 billion Term Loan Credit Agreement executed on January 8, 2026, consisting of $3.5 billion due in 364 days and $500 million maturing in two years. The loans carry interest rates of Term SOFR plus 87.5 to 135 basis points, depending on Waters' credit rating, with the shorter-term tranche subject to quarterly rate increases.
Strategic Rationale
The combination creates a comprehensive life sciences and analytical instruments powerhouse, merging Waters' expertise in liquid chromatography and mass spectrometry with BD's flow cytometry and cell analysis capabilities. The Biosciences division brings established positions in immunology, cell biology, and protein analysis that complement Waters' strengths in pharmaceutical and environmental testing markets.
For BD, the spin-off allows the company to sharpen its focus on its core medical technology and healthcare delivery solutions while unlocking value for shareholders through the tax-efficient separation. The $4 billion cash payment provides BD with capital for strategic investments in its remaining businesses.
Waters gains immediate scale in the high-growth cell analysis market and expands its addressable market in biologics development and manufacturing. The combined entity will have enhanced capabilities across the drug discovery and development continuum, from early research through quality control.
What to Watch
Integration execution presents the immediate challenge, with Waters entering into a Transition Services Agreement with BD to ensure operational continuity. The company must manage the integration while maintaining business momentum across both legacy organizations.
Debt management will require attention, with Waters' leverage ratio covenant set at 3.50 to 1.00, temporarily increased to 4.25 to 1.00 for the merger. The company faces $3.5 billion in debt refinancing within 364 days, likely through permanent financing or asset sales.
The Employee Matters Agreement and Intellectual Property Matters Agreement will govern the separation of personnel and technology assets between BD and the combined entity. Waters added Dr. Claire M. Fraser to its board as part of the merger agreement, expanding the board from 10 to 11 members.
Regulatory considerations appear minimal given the transaction's closing, but Waters must now demonstrate the strategic benefits of the combination through revenue synergies and operational efficiencies. The company's ability to cross-sell complementary technologies and accelerate innovation in converging markets will determine the merger's long-term success.
The transaction represents one of the largest deals in the analytical instruments sector, positioning Waters to compete more effectively with larger rivals like Thermo Fisher Scientific and Danaher in the growing life sciences tools market.
*Source: Waters Corporation Form 8-K filed February 9, 2026*